Congo-Kinshasa: Ebola Crisis-The Vaccines Debate

[Ghanaian Times] As I write this piece, the Democratic Republic of Congo (DRC) is reeling from an Ebola crisis with the World Health Organization (WHO) having declared it a global health emergency. It is reported to have killed about 1,800 people so far. The crisis has been worsened by internal conflicts and mobility of people fleeing from the conflicts. I will continue with information gleaned from the BBC and Bloomberg on the Ebola crisis and deployment of vaccines.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

Publication date: Available online 18 September 2019Source: Social Science &MedicineAuthor(s): Yuxi Wang, Martin McKee, Aleksandra Torbica, David StucklerAbstractContemporary commentators describe the current period as “an era of fake news” in which misinformation, generated intentionally or unintentionally, spreads rapidly. Although affecting all areas of life, it poses particular problems in the health arena, where it can delay or prevent effective care, in some cases threatening the lives of individuals. While examples of the rapid spread of misinformation date back to the earliest days of scientific med...
Source: Social Science and Medicine - Category: Psychiatry & Psychology Source Type: research
KENILWORTH, N.J.--(BUSINESS WIRE)-- September 17, 2019 -- Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) and granted...
Source: - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
The organization granted Breakthrough Therapy Designation to V920 in July 2016 and it now has a target action date of March 14, 2020
Source: - Category: Pharmaceuticals Source Type: news
Ebola virus (EBOV) is a non-segmented negative-sense RNA virus that causes a severe human disease. The ongoing EBOV outbreak in the Eastern part of Democratic Republic of the Congo has resulted to date in over 2500 confirmed cases including over 1500 deaths. Difficulties with vaccine administration indicate the necessity for development of new general drugs and therapeutic strategies against EBOV. Host Ser/Thr protein phosphatases, particularly PP1 and PP2A, facilitate EBOV transcription by dephosphorylating the EBOV VP30 protein and switching activity of the polymerase complex toward replication. Previously, we developed ...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
ACS NanoDOI: 10.1021/acsnano.9b03660
Source: ACS Nano - Category: Nanotechnology Authors: Source Type: research
Dr Catherine Houlihan, from Aberdeen, returned home to the UK from the African nation in June after spending a month at the heart of the epidemic in the North Kivu province.
Source: the Mail online | Health - Category: Consumer Health News Source Type: news
by Dan Lu, Kefang Liu, Di Zhang, Can Yue, Qiong Lu, Hao Cheng, Liang Wang, Yan Chai, Jianxun Qi, Lin-Fa Wang, George F. Gao, William J. Liu Bats harbor many zoonotic viruses, including highly pathogenic viruses of humans and other mammals, but they are typically asymptomatic in bats. To further understand the antiviral immunity of bats, we screened and identified a series of bat major histocompatibility complex (MHC) I Ptal-N*01:01– binding peptides derived from four different bat-borne viruses, i.e., Hendra virus (HeV), Ebola virus (EBOV), Middle East respiratory syndrome coronavirus (MERS-CoV), and H17N10 influenz...
Source: PLoS Biology: Archived Table of Contents - Category: Biology Authors: Source Type: research
by Gertrud U. Rey The Democratic Republic of the Congo (DRC) is currently experiencing its worst outbreak of Ebola virus disease in history. More than 3,000 people have been infected with the virus, and nearly 1,900 have died since the outbreak began in 2018. The causative virus is “Ebola virus”, the strain previously known as […]
Source: virology blog - Category: Virology Authors: Tags: Basic virology Information antiviral antibodies ebola virus mAb-114 monoclonal antibody neutralizing antibodies non-neutralizing antibodies passive vaccine REGN-EB3 viruses Source Type: blogs
MCMi regulatory science project to research issues that are key to understanding and predicting if —and how—vaccines and therapeutics to prevent and treat Ebola will show efficacy
Source: FDA Center for Drug Evaluation and Research - What's New - Category: Drugs & Pharmacology Authors: Source Type: news
New vaccine from J&J could supplement current shot from Merck
Source: - Drugs and Healthcare - Category: Pharmaceuticals Source Type: news
More News: African Health | Congo Health | Ebola | Ebola Vaccine | Emergency Medicine | Ghana Health | International Medicine & Public Health | Vaccines | WHO